top of page

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

Play Video

TOP VIDEO: Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and more | 05/30/25

Latest Videos

faunda_linda_goodman (720p)

Play Video

AI News:

Fauna Bio launched Fauna Brain, an AI platform that uses internal and external data, to identify and score targets

06/20/2025

Welcoming Genezen as a new sponsor to BiotechTV

Play Video

Genezen:
Welcoming Genezen as a new sponsor to BiotechTV - a best-in-class CDMO.

Sponsored

The Co-Director of Cardiff University's Medicines Discovery Institute talks about the specialized work that happens here in neuroscience, cancer, and beyond | 06/20/25

Play Video

From Cardiff, Wales:

The Co-Director of Cardiff University's Medicines Discovery Institute talks about the specialized work that happens here

06/20/2025

SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond | 06/20/25

Play Video

From London:

SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of biotech

06/20/2025

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences | 06/19/25

Play Video

AI News:

Infinimmune launched its GLIMPSE-1 antibody engineering platform that is focused on native human antibody sequences

06/18//2025

Shows

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising environment around this year's conference, and how gene therapy might be insulated from the competition from China that other areas have been feeling.

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous malformation, targets such as MALT1, LSD1, CDK7, and more.

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the lupus program is progressing.

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination approach in breast cancer. Plus, Parkinson's, hematology, and more.

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in muscle biology Cytokinetics has built over three decades.

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the multitude of factors (AI, human intelligence, nature) that must be included in the drug development process.

2025 SF Healthcare Week

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

15:21

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

09:08

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

19:01

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XSTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

09:58

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

08:29

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

11:26

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

11:00

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

12:14

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.

#ASCO25

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric, and more.

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

He discusses Autolus' 'fast off' approach to CAR-T and why he believes the safety benefits led to no REMS requirement for Aucatzyl. Plus, ASH presentations, and how Autolus is the only company using a commercially approved CD19 construct in clinical trials for autoimmune disease.

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's approach to autommite, a glioblastoma program, and more.

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future competitors' data at ASH, other programs, including autoimmune, and plans for an R&D center in Philadelphia.

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program Lacutamab and an NK engager program Sanofi is partnered on.

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others. Plus ASH data for Brukinsa and a BLC2, and how BeiGene's investments in global scale are bearing fruition.

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

He comments on data at ASH including tafasitamab, axitilimab, and the company's BET inhibitor. Plus, news from yesterday on Incyte's PD1, and looking forward to next year.

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active sites, and how this is different than the approaches of other companies. He describes CellCentric's phase 2 data at ASH and the next steps for the program.

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page